Protein associated with growth of tumors may prevent the spread of cancer

	Tweet

A protein associated with the growth of head and neck tumors may be a tumor suppressor that could prevent the spread of cancer when it is expressed above normal levels, according to a study published in the Journal of the National Cancer Institute (JNCI).

The study, led by University of Pittsburgh School of Medicine professor of otolaryngology and pharmacology, Jennifer Grandis, M.D., is the first to show that the expression of a protein called STAT1 may play a vital role in preventing head and neck tumor growth. STAT1 belongs to a family of proteins called signal transducers and activators of transcription that have been linked to tumor progression in many cancers.

“While the activation of STAT1 has been associated with increased survival in breast cancer patients, its role in head and neck cancer has not been clearly understood,” said Dr. Grandis.

“Our study reveals that it is a critical survival pathway in head and neck cancer and that therapeutic strategies to restore its functioning may be of benefit to patients.”

Dr. Grandis, who also is director of the Head and Neck Cancer Program at the University of Pittsburgh Cancer Institute (UPCI), and colleagues compared the expression of STAT1 in squamous cell carcinoma of the head and neck (SCCHN) tumors to its expression in normal tissue samples. They found that STAT1 was expressed in lower levels in the tumor cells than in the normal cells. And, when they chemically altered the expression of STAT1 to increase its levels, the cancer cells diminished and died.

To alter the expression of STAT1, the researchers treated cells with an agent that removes methyl groups and modifies gene expression. Some of the SCCHN cells were then treated with chemotherapy alone and others in combination with azacytidine, an agent that reversed the process and increased STAT1 production. Those cells treated with chemotherapy and azacytidine were more responsive to the treatment and more likely to stop growing and eventually die.

“When STAT1 signaling was silenced, the tumor cells grew indicating to us that its loss promotes cancer growth,” said Dr. Grandis. “On the other hand, when the signaling was increased and combined with chemotherapy, cancer cells were more likely to die.”

More than two-thirds of head and neck cancer patients have a locally advanced stage when diagnosed. The disease has a poor five-year survival rate even after treatment. Current treatment options are limited and often cause disabling side effects.

http://www.upmc.com

RELATED STORIES:
Genetic Risk Factor Found for Head and Neck Cancer in Smokers   Tooth Loss Linked to Esophageal, Head and Neck, and Lung Cancer   Blue light used to harden tooth fillings stunts tumor growth   Signaling System Found that Halts the Growth of a Childhood Brain Cancer   Gene therapy increases survival for end-stage head and neck cancer   New procedure to make brain surgery safer   UVA Brain Cancer Trials Lead to FDA Accelerated Approval of Medication   New technique holds promise for rare eye cancer   Acrylamide not tied to thyroid, head-neck cancers   Tobacco and alcohol use independently increase risk of head and neck cancer   Does Green Tea Prevent Cancer? Evidence Continues to Brew, But Questions Remain   Early detection critical in treating pediatric thyroid cancer   A new radiation therapy treatment developed for head and neck cancer patients   Target for Therapeutic Drugs to Fight Most Common Adult Brain Cancer   IMRT improves outcomes in patients with extranodal lymphoma of the head and neck   Protein Expression Holds Promise for Head and Neck Cancer Detection   HIV-positive head and neck cancer patients benefit from radiation therapy   Radiotherapy Advance Builds Hope for Noninvasive Brain Cancer Treatment   Brain Cancer Experts and Resources at Johns Hopkins   Convergence in head and neck cancer   Enhanced treatment of brain tumors   Vaccine against deadly brain cancer shows promise

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]